title: Linezolid for gram-positive infections.
abstract: Linezolid (Zyvox--Pharmacia)--the first oxazolidinone antibacterial--is marketed in the UK for treating hospital- and community-acquired pneumonia, skin and soft tissue infections. The manufacturer claims that switching from i.v. to oral administration of linezolid needs no dose adjustment and "will lead to early patient discharge and reduced hospital length of stay" for patients needing treatment for infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Here, we assess the place of linezolid.
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D008996:Monoamine Oxidase Inhibitors; D023303:Oxazolidinones; D000069349:Linezolid